Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-10-17
2006-10-17
Rao, Deepak (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S275000, C544S317000, C544S323000, C544S324000
Reexamination Certificate
active
07122552
ABSTRACT:
The present invention provides a compound of formula I:or a pharmaceutically acceptable salt thereof. These compounds are inhibitors of protein kinases, particularly inhibitors of JAK and CDK2 mammalian protein kinases. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of utilizing those compounds and compositions in the treatment of various protein kinase mediated disorders.
REFERENCES:
patent: 0 086 422 (1983-08-01), None
patent: WO 02/04429 (2002-01-01), None
Thompson, PubMed Abstract (Drug News Perspect. 18(5):305-10), Jun. 2005.
O'Shea et al., PubMed Abstract (Curr Opin Rheumatol. 17(3):305-11), May 2005.
Casanova et al., PubMed Abstract (Rev Neurol. 28(9):909-15), May 1999.
Douglas, Jr. Introduction to Viral Diseases, Cecil Textbook of Medicine, 20thEdition, vol. 2, pp. 1739-1747, 1996.
Simone, Oncology: Introduction, Cecil Textbook of Medicine, 20thEdition, vol. 1, pp. 1004-1010, 1996.
Blain et al., Differential Interaction of the Cyclin-dependent Kinase (Cdk) Inhibitor p27 with Cyclin A-Cdk2 and Cyclin D2-Cdk4, The Journal of Biological Chemistry, vol. 272, No. 4, pp. 25863-25872, 1997.
LuValle et al., Cell Cycle Control in Growth Plate Chondrocytes, Frontiers in Bioscience 5, pp. d493-503, May 2000.
Changelian et al., “Prevention of organ allograft rejection by a specific janus kinase 3 inhibitor,” Science, 302:875-878 (2003).
Malaviya et al., “Treatment of allergic asthma by targeting janus kinase 3-dependent leukotriene synthesis in mast cells with 4-(3',5'—dibromo-4'-hydroxyphenyl)amino-6,7-dinethoxyquinazoline (WHI-P97),” The Journal of Pharmacology and Experimental Therapeutics, 295(3):912-926 (2000).
Trieu et al., “A specific inhibitor of janus kinase-3 increases survival in a transgenic mouse model of amyotrophic lateral sclerosis,” Biochemical and Biophysical Research Communications, 267:22-25 (2000).
Brown Karen E.
Rao Deepak
Vertex Pharmaceutical Incorporated
Vertex Pharmaceuticals Incorporated
LandOfFree
Inhibitors of JAK and CDK2 protein kinases does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibitors of JAK and CDK2 protein kinases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of JAK and CDK2 protein kinases will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3716561